Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Solid Tumor × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 47 Hodgkin Disease 25 Lymphoma 13 Sarcoma 7 Skin Neoplasms 6 Neoplasm Metastasis 6 Uveal Melanoma 5 Leiomyosarcoma 5 Neoplasms 4 Solitary Fibrous Tumors 2 Sarcoma, Synovial 2 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroblastoma 1 Melanoma Neoplasms 1 Liposarcoma 1 Immunotherapy 1 Histiocytoma, Malignant Fibrous 1 Hematologic Diseases 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1

Interventions

senaparib 7 pembrolizumab 6 Irinotecan 6 Paclitaxel 5 Docetaxel 5 Cisplatin 5 Capecitabine 5 Fluorouracil 4 Rifampin 3 Midazolam 3 Leucovorin 3 Itraconazole 3 Injections 3 Bevacizumab 3 pertuzumab 2 ontuxizumab 2 atezolizumab 2 Nivolumab 2 Gemcitabine 2 vofatamab 1 tremelimumab 1 trastuzumab duocarmazine 1 talazoparib 1 sotorasib 1 sintilimab 1 saracatinib 1 ridaforolimus 1 regorafenib 1 prexasertib 1 pexidartinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡